Table 1

Demographics and clinical features of participants

Belimumab
(n=28)
Placebo
(n=26)
Total
(n=54)
Female, n (%)26 (93)21 (81)47 (87)
Age (years)*33.6±12.233.7±11.233.6±11.6
Race/ethnicity, n (%)
 Asian17 (61)12 (46)29 (54)
 White8 (29)12 (46)20 (37)
 Black3 (11)2 (8)5 (9)
Kidney biopsy LN class, n (%)
 III or IV18 (64)15 (58)33 (61)
 III/IV and V6 (21)6 (23)12 (22)
 V4 (14)5 (19)9 (17)
Background therapy with MMF, n (%)15 (54)17 (65)32 (59)
Complete responders, n (%)†18 (67)13 (50)31 (58)
  • *Mean±SD.

  • †One participant in the belimumab group was missing clinical information required to determine response. Thus, a denominator of n=27 in the belimumab group and total n=53 were used in percentages for this row.

  • LN, lupus nephritis; MMF, mycophenolate mofetil.